Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF) | MicrobiomeTrials← Back to trialsNCT05938465
Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF)
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2023-11-06Est. Completion: 2027-05-31
Enrollment target: 50 participants Locations- Cedars-Sinai Medical Center, Los Angeles, California, United States
- Mayo Clinic - Florida (Inflammatory Bowel Disease Center), Jacksonville, Florida, United States
- Corewell Health, Grand Rapids, Michigan, United States
- Mayo Clinic Department of Gastroenterology, Rochester, Minnesota, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- NYU Langone Health, New York, New York, United States
- University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
- Penn State Health (Milton S. Hershey Medical Center), Hershey, Pennsylvania, United States
Other microbiome trials you might be interested in
Pouchitis
The researchers propose conducting a multi-center, randomized, placebo-controlled study to investigate the potential rol…
New York, United StatesEst. completion Feb 6, 2030
Ulcerative ColitisIleal Pouch
Ulcerative colitis (UC) is a disease that causes long-term inflammation in the digestive tract, and many people with thi…
Ann Arbor, United StatesEst. completion May 2029
Phase 3
Recruiting
Familial Adenomatous Polyposis (FAP)
The main goal of this clinical trial is to learn if the drug eRapa works to slow down the progression of disease in pati…
Arcadia, United StatesEst. completion Jul 2030